OKI-179 is under clinical development by OnKure and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OKI-179’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OKI-179 is under development for the treatment of triple-negative breast cancer, melanoma, colorectal cancer and hematological malignancies. It is administered through the oral route. The drug candidate is a derivative of largazole. It acts by targeting class I histone deacetylases 1, 2 and 3.
OnKure is a drug developer that discovers and develops epigenetic therapies for the treatment of cancer. The company offers production of specific histone deacetylases inhibitors. Its lead product candidate ONK102 significantly reduces the growth rate of tumors in hematological, and solid tumor cancers, when dosed by itself or in combination with other targeted therapies. In addition, the company also discovers HDAC 6 inhibitors that are among the most potent and selective agents. It collaborates with veteran consultants and advisors for pre-clinical and clinical development activities. OnKure is headquartered in Longmont, Colorado, the US.
For a complete picture of OKI-179’s drug-specific PTSR and LoA scores, buy the report here.